Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

YOU WONT BELIEVE: Merck - You Need To See This

The $11 Billion Reason TECH Stock Is Up Today

Bio-Techne stock rallies as Merck announces an agreement to acquire it for $73 per share. But is there any further upside left in TECH shares?

Barchart

How to Buy Merck Stock for a 10% Discount or Achieve an 11% Annual Return

On Monday, with Merck trading at $119.60, the August put option with a strike price of $110 was trading around $2.03. Traders selling this put would receive $230 in option premium. In return for receiving this premium, they have an obligation to buy 100 shares of MRK for $110.

Barchart

CKGSB Hosts 10th Economic Symposium in Beijing, Spotlighting China-ASEAN and China-Europe Economic Ties

BEIJING, June 22, 2026 /PRNewswire/ -- Cheung Kong Graduate School of Business (CKGSB), a leading business school in China, hosted its 10th Economic Symposium at its new Beijing campus. The forum brought together ambassadors, policymakers, business leaders, and scholars to examine China's economic outlook and its evolving relationships with ASEAN…

AAP

From analysis to the latest developments in health,
read the most diverse news in one place.

Global drugmakers rush to boost US presence as tariff threat looms

Global drug companies are boosting U.S. production and stockpiling medicines. This is a response to potential tariffs on branded drugs. Companies are investing billions in new plants and expanding existing facilities across America. These moves aim to avoid penalties and ensure supply chains remain robust. Several major pharmaceutical firms have…

The Economic Times

The Hashgraph Group and Merck Introduce EU Digital Product Passport on Hedera for Regulated Supply Chains

ZURICH, June 9, 2026 /PRNewswire/ -- The Hashgraph Group (THG) today announced a strategic collaboration with science and technology company Merck, that extends its TrackTraceDigital Product Passport (DPP) platform. Built on Hedera and designed to support compliance requirements for the global supply chain industry, the collaboration aims to meet the…

AAP

Alpha Tau Medical Sets Up Catalyst-Rich 2026 as Key Cancer Trial Data Nears

Alpha Tau Medical (NASDAQ:DRTS) outlined a series of clinical and regulatory updates during the Lytham Partners Spring 2026 Investor Conference, with Raphi Levy of Alpha Tau telling investors the company’s most important trials are “coming to a head” over the coming months. Levy said the company is

MarketBeat

Exelixis Eyes CABO Growth as Zanzalintinib Readouts and Potential CRC Launch Near

Exelixis (NASDAQ:EXEL) remains focused on expanding its CABO franchise while preparing for potential launches and data readouts tied to zanzalintinib, Andrew Peters, the company’s senior vice president of strategy, said during a session hosted by RBC Capital Markets. Peters said Exelixis’ guidance

MarketBeat

Read news from The Economist, FT, and more,
with one subscription

Dow Hits New High as Warsh Takes Fed Oath: Stock Market Today

President Donald Trump welcomed Fed Chair Kevin Warsh the same way President Ronald Reagan welcomed Fed Chair Alan Greenspan.

Kiplinger

Merck KGaA Q1 Earnings Call Highlights

Merck KGaA (ETR:MRK) reported what executives described as a “solid start” to 2026, with organic growth in its Life Science and Electronics businesses offsetting a decline in Healthcare, and raised its full-year outlook after stronger momentum late in the quarter. Group Chief Executive Officer Kai

MarketBeat

Inhibrx Biosciences’ INBRX-106 Combo Tops KEYTRUDA Alone in Phase 2 Cancer Study

Inhibrx Biosciences (NASDAQ:INBX) reported interim randomized Phase 2 data for INBRX-106 in combination with Merck’s KEYTRUDA in first-line PD-L1-positive head and neck squamous cell carcinoma, with Chief Executive Officer Mark Lappe saying the results showed a higher confirmed response rate and dee

MarketBeat

Clinical trials that are actually marketing ploys targeting doctors – how seeding trials put profit over patients

Some clinical trials aren’t designed to answer scientific questions. They’re designed to market drugs. In our recently published research, my team and I analyzed over 34,000 industry-funded trials and found that hundreds of studies across seven medical fields were likely designed to promote a drug to physicians rather than to…

The Conversation

Wall Street Says Buy Merck Over Pfizer. The Numbers Tell a More Complicated Story.

A tougher market puts two healthcare dividend giants in focus, as investors weigh income, stability, valuation, and long-term upside.

Barchart

This Merck (MRK) Stock Bullish Diagonal Trade Targets a Price of $130 by June 18

A bullish diagonal spread is an advanced option trade and generally not suitable for beginners, but it can have its place within an option portfolio.

Barchart

Merck Just Made a Big Bet on a New Cancer Growth Engine

Merck's $6.7 billion Terns acquisition bolsters its oncology pipeline while reinforcing its strong margins, steadily growing dividend, and long-term growth.

MarketBeat

Get all your
news in one place.

100's of premium titles.
One news app.

MarketBeat

3 Undervalued Names Too Cheap to Ignore

Three prominent names across the biopharma and consumer staples spaces offer the potential for value plays with room for fundamental growth as well.

The Independent UK

Experimental pill may offer new cholesterol-lowering option for millions

There are other pills that patients can add to their statin

Euronews

Promising vaccine for aggressive melanoma could unlock the body’s potential to fight cancer

A personalised mRNA vaccine developed by Moderna and Merck shows lasting benefits for patients with high-risk skin cancer.

The Independent UK

New personalized skin cancer treatment shows success in preventing return of high-risk melanoma

Patients with severe melanoma who received the treatment were 49% less likely to die or have their cancer return, pharmaceutical companies Moderna and Merck announced in five-year findings.

Get all your
news in one place.

100's of premium titles.
One news app.

MarketBeat

3 “Forever Stocks” to Hold When the Market Won’t Sit Still

Chevron, Colgate-Palmolive, and Merck highlight how dividends, durable businesses, and long-term growth drivers can support a buy-and-hold investment strategy

We Got This Covered

Today in ‘great’ America: Donald Trump decides to prove he can’t negotiate to save his life

What an awful deal.

The Guardian - UK

Life-saving therapies are being delayed as research funding dries up

Letter: Dr Carol S Leonard writes that mRNA vaccines are a way forward for those with melanoma, but hopes are dashed by financial cuts

The Independent UK

More drug companies sign on to Trump’s health exchange that promises to lower prescription prices

Administration officials say the ‘Trump Rx’ website should be up and running next month

Evening Standard

Boss of drugs giant GSK declares US best place to invest

Dame Emma Walmsley said the US was still leading the way for new drugs and vaccines.

The Guardian - UK

What will be the cost of Keir Starmer’s new medicines deal with Donald Trump? British lives

More than £3bn that could have been used for UK patients will go to big pharma for its branded products, says Guardian columnist Aditya Chakrabortty

MarketBeat

Dividend Stocks for 2026: Where to Invest as the Market Cools

These three dividend heavyweights offer attractive yields and upside potential heading into what could be an uncertain 2026.

1 2 3 4 5

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.